MOTS-c Dosage Chart | Protocol Guide

MOTS-c Dosage Chart | Protocol Guide. MOTS-c dosage chart for research: 5–10mg ranges, frequency and cycle conventions, plus 10mg vial reconstitution and U-100 syringe math. Key Takeaways The commonly reported research range is 5–10mg per exposure. That is a convention from experimental and community protocols, not an approved human dose. Frequency is usually intermittent. Protocol reports commonly describe one to three exposures per week rather than daily administration. Cycles are typically short. Four-week blocks appear often, with some protocols extending to six weeks and including an off-cycle observation period. A 10mg vial plus 2mL BAC water equals 5mg/mL. On a U-100 syringe, 10 units then represents 0.5mg and the full 10mg vial contains 200 units. MOTS-c is not FDA-approved. Published evidence is mainly preclinical; CB4211 is a modified analog and should not be treated as proof of an unmodified MOTS-c dosing schedule. MOTS-c dosage discussions usually converge on a 5–10mg research range , administered intermittently one to three times per week in short four- to six-week study blocks. Those numbers describe conventions reported in laboratory-adjacent and community protocols. They are not prescribing instructions, and no regulator has established an approved human MOTS-c dose. This guide keeps three things separate: the amounts researchers commonly report, the arithmetic required to prepare a 10mg vial, and the much narrower conclusions supported by published research. For the regulatory and human-data picture, use our separate MOTS-c clinical trials status review. That article remains focused on trials; this page is the calculation reference. MOTS-c Dosage Chart The chart below summarizes the most frequently discussed research amounts. It is a map of reported conventions, not a recommendation. The U-100 conversions assume a 10mg vial reconstituted with 2mL of bacteriostatic water, producing 5mg/mL. Research amount Volume at 5mg/mL U-100 units Share of 10mg vial 0.5mg 0.10mL 10 units 5% 1mg 0.20mL 20 units 10% 2.5mg 0.50mL 50 units 25% 5mg 1.00mL 100 units 50% 7.5mg 1.50mL 150 units 75% 10mg 2.00mL 200 units 100% A key practical point is visible in the table: the commonly cited 5–10mg band is a large volume when 2mL is used. Five milligrams equals a full 1mL U-100 syringe, while 10mg equals 2mL and cannot fit in a standard 1mL barrel at once. A chart can verify arithmetic; it does not resolve route, volume tolerance, sterility, or protocol suitability. Typical MOTS-c Research Range, Frequency, and Cycle Protocol variable Commonly reported convention Evidence limitation Amount 5–10mg per exposure No approved clinical label for unmodified MOTS-c Frequency 1–3 times weekly Varies widely across informal protocols Cycle 4 weeks; sometimes 4–6 weeks No controlled trial validates a standard cycle Off-cycle 2–4 weeks of observation is often described A convention, not a proven washout requirement Study timing Often separated from meals or exercise endpoints Timing claims have not been established clinically The most defensible interpretation is that 5–10mg is a reported convention , not a clinically derived target. Researchers should predefine endpoints, avoid changing multiple variables together, and record the actual mass, concentration, frequency, cycle length, storage interval, and batch documentation. That produces a reproducible study record instead of a loose “protocol.” Example research schedules seen in protocol discussions Schedule model Reported exposure Four-week total 10mg vials required mathematically Conservative observation model 5mg once weekly 20mg 2 vials Twice-weekly model 5mg twice weekly 40mg 4 vials High-frequency model 5mg three times weekly 60mg 6 vials Higher-amount model 10mg once weekly 40mg 4 vials These examples exist to expose the total compound requirement. They do not establish that one schedule is effective or safe. A protocol claiming 5mg twice weekly for four weeks consumes 40mg, so a single 10mg vial plainly cannot support the stated cycle. How to Reconstitute a 10mg MOTS-c Vial Reconstitution math starts with one equation: vial mass ÷ water volume = concentration . Adding 2mL of bacteriostatic water to a 10mg vial gives: 10mg ÷ 2mL = 5mg/mL Confirm that the label states 10mg and match the vial to its batch-specific certificate of analysis. Record the diluent, lot, date, and intended final volume before handling the vial. Using aseptic laboratory technique, introduce 2mL of BAC water slowly against the vial wall rather than forcefully onto the lyophilized material. Allow the powder to dissolve without vigorous shaking. Gentle rolling is used to limit foaming and mechanical stress. Label the resulting solution 5mg/mL , with the reconstitution date and storage conditions required by the protocol. Bacteriostatic water is a multidose diluent, not a guarantee that a preparation remains sterile. Institutional aseptic procedures, vial integrity, temperature control, and the diluent manufacturer’s directions govern handling. Do not infer a universal beyond-use date from an internet dosage chart. U-100 Syringe Math for MOTS-c A U-100 syringe is a volume scale: 100 units = 1mL , so one unit equals 0.01mL. At 5mg/mL, each unit contains 0.05mg, or 50 micrograms. Requested mg ÷ 5mg/mL × 100 = U-100 units U-100 mark Liquid volume MOTS-c at 5mg/mL 1 unit 0.01mL 0.05mg (50mcg) 5 units 0.05mL 0.25mg 10 units 0.10mL 0.5mg 20 units 0.20mL 1mg 50 units 0.50mL 2.5mg 100 units 1.00mL 5mg Alternative BAC-Water Volumes for a 10mg Vial Changing water volume changes concentration and U-100 units, but never the total 10mg mass in the vial. BAC water added Final concentration MOTS-c per U-100 unit Units for 5mg 1mL 10mg/mL 0.10mg 50 units 2mL 5mg/mL 0.05mg 100 units 2.5mL 4mg/mL 0.04mg 125 units 3mL 3.33mg/mL 0.033mg 150 units Never copy a syringe-unit number from a protocol without copying its vial strength and water volume too. “20 units” represents 1mg at 5mg/mL, but 2mg at 10mg/mL. Units are not milligrams. What Published MOTS-c Research Actually Supports MOTS-c was identified as a 16-amino-acid mitochondrial-derived peptide in research linking it to metabolic homeostasis and insulin sensitivity in animal models. The foundational Cell Metabolism paper (PMID 25738459) reported protection against age- and diet-dependent insulin resistance in mice. Later work found that MOTS-c can translocate to the nucleus during metabolic stress and regulate adaptive gene expression; see the Cell Metabolism study (PMID 29983246) . Human exercise studies have examined endogenous MOTS-c responses, while much of the exogenous dosing literature remains based on rodents. CB4211 reached Phase 1 as a modified MOTS-c analog, but its pharmacology and clinical study schedule cannot simply be transferred to unmodified research-vial MOTS-c. This gap is why protocol language on this page stays descriptive. MOTS-c Protocol Design: What to Record Identity: peptide name, sequence or specification, vial label, lot number, and batch-matched analytical report. Preparation: starting mass, diluent type and volume, calculated concentration, date, and storage log. Exposure: amount in mg, liquid volume, U-100 units if applicable, frequency, and cumulative cycle total. Endpoints: predefined metabolic, exercise, biochemical, or tissue endpoints appropriate to the model. Confounders: feeding state, training load, temperature, handling, other compounds, and changes in measurement methods. Stopping rules: protocol-defined adverse findings, contamination, precipitation, labeling mismatch, or broken cold-chain conditions. MOTS-c is also prohibited under the World Anti-Doping Agency’s S4 hormone and metabolic modulators category. Tested athletes should not interpret “research use” as an exemption. Where to Source MOTS-c for Laboratory Research Stock status matters more than an old affiliate relationship. As checked on August 19, 2026 , every MOTS-c pack at Peptide Partners was out of stock, so this page does not present Partners as the available source. Peptide Plugs MOTS-c 10mg was listed in stock, with 654 units shown at the time checked. The existing registry code is PSTACK for eligible first orders; confirm inventory, code acceptance, product labeling, and batch documents at checkout because these can change. A vendor image or inventory counter is not analytical evidence. Before acquisition, look for a batch-specific COA that matches the lot, identity testing in addition to a purity percentage, clear vial mass, and documented shipping and storage conditions. MOTS-c Dosage FAQ What is the typical MOTS-c dosage in research protocols? The commonly reported convention is 5–10mg per exposure, often one to three times weekly. No FDA-approved human dose exists, and published preclinical schedules should be interpreted within their specific model rather than converted into prescriptions. How many U-100 units is 5mg of MOTS-c? With a 10mg vial reconstituted using 2mL, the concentration is 5mg/mL. Five milligrams is therefore 1mL, or 100 U-100 units. How many units is 10mg of MOTS-c? At 5mg/mL, 10mg equals 2mL or 200 U-100 units. That exceeds the capacity of a standard 1mL U-100 syringe; this is a mathematical conversion, not handling advice. How long is a MOTS-c cycle? Four-week blocks are commonly described, with some informal protocols extending to six weeks and then using an observation interval. No controlled trial establishes an optimal unmodified MOTS-c cycle. Is CB4211 dosing the same as MOTS-c dosing? No. CB4211 is a modified MOTS-c analog developed as a drug candidate. Its trial protocol and pharmacokinetics cannot be treated as a validated dosage for unmodified MOTS-c. Is this MOTS-c dosage chart medical advice? No. It documents reported research conventions and verifies concentration and syringe-volume math. MOTS-c is not FDA-approved for human use, and this article does not diagnose, prescribe, or recommend treatment. Research-use disclaimer: MOTS-c discussed here is for laboratory research only and is not intended for human consumption. This page is educational, not medical advice. Protocol conventions are not proof of safety or efficacy. PeptideStack page context: visitors can use the header navigation to reach the product catalog, blog, calculators, supplier pages, discount-code pages, contact page, legal policies, privacy policy, terms, and research disclaimer. The site is organized around research peptide education, supplier transparency, product comparison, vendor review content, discount-code tracking, and calculator tools for reconstitution or unit conversion research planning. PeptideStack separates research-use-only peptide information from FDA-approved medication and licensed telehealth pathways. Research peptide pages are informational and are not medical advice, prescription guidance, dosing instructions, treatment recommendations, or instructions for human consumption. Many pages include affiliate disclosures because PeptideStack may earn a commission when visitors click external supplier or telehealth links. That commission does not change the price paid by visitors and does not mean PeptideStack manufactures, sells, distributes, compounds, or ships peptides or medications. Supplier and product pages should be evaluated for third-party testing, batch-specific certificates of analysis, named laboratory verification, transparent pricing, realistic delivery expectations, payment security, refund policies, support quality, and consistent research-use-only labeling. Blog pages connect related guides, comparison articles, FDA approval status explainers, safety context, legality resources, product pages, vendor reviews, and calculator tools so visitors can keep researching without relying on a single supplier claim. Calculator pages are educational tools for laboratory planning and should be cross-checked against professional protocols, institutional requirements, and applicable laws. Legal and disclaimer pages explain the boundaries of PeptideStack content and the responsibility of visitors who evaluate third-party vendors. The rendered interface may add interactive details such as mobile navigation labels, product tabs, share buttons, related article cards, disclosure boxes, call-to-action buttons, vendor selectors, copy-code controls, email-code forms, footer navigation, and status labels. The static HTML fallback includes this context so the same page purpose is understandable before the JavaScript application finishes loading. Visitors should treat PeptideStack as a research and comparison starting point. Final supplier evaluation should include direct review of the external vendor website, current product availability, checkout terms, applicable laws, institutional requirements, and any third-party laboratory documentation available for the exact product or batch being considered. Footer resources repeat important sitewide context: PeptideStack is independent, affiliate-supported, research-focused, and not a pharmacy or manufacturer. Pages may include links to the iOS app, calculators, blog hubs, product hubs, supplier comparisons, support contact, and policy documents. This repeated context is intentionally available in the raw HTML for crawlers that inspect a page before executing the React bundle. Raw HTML also includes page summaries for mobile crawlers using JavaScript rendering, desktop crawlers comparing source to rendered output, accessibility tools, and no-script visitors. The fallback is replaced by the React app in normal browsers but keeps the source document aligned with the visible page topic. This fallback keeps source HTML and rendered HTML closer for crawl diagnostics and SEO audits across crawled pages, routes, reports, and recrawls.